CIRM Clinical Trial and Biotech Industry Loan Plans Remain Veiled
With only two days remaining before this week's meeting of the board of directors of the California stem cell agency, still missing publicly are any details on proposals that appear to involve hundreds of millions of dollars in taxpayer funds.
The plans concernCIRM's fledgling $500 million biotech loan program and participaton in funding of clinical tria…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.